Oral Oncol:对口咽癌患者的高危人乳头瘤病毒蛋白亚型特异性抗体的评估

2017-06-28 MedSci MedSci原创

高危人乳头瘤病毒(HR-HPV)感染会导致一小组口咽癌(OPSCC)亚群的发生,但它们对治疗的反应较好。然而,对于归因于HR-HPV癌症的普遍可接受的界定还未出现。

高危人乳头瘤病毒(HR-HPV)感染会导致一小组口咽癌(OPSCC)亚群的发生,但它们对治疗的反应较好。然而,对于归因于HR-HPV癌症的普遍可接受的界定还未出现。

研究通过PCR扩增和测序检测p16INK4A过表达和HR-HPV DNA来筛选由HR-HPV引发OPSCC的患者。随后通过多路复用血清学技术详细检测HR-HPV亚型特异性的抗体反应。

结果显示,50患者有可能罹患研究所需肿瘤。26/50个(52%)肿瘤样本经检测p16INK4A 表达和HR-HPV DNA (22例HPV16, 4例HPV33)呈阳性。这26/26例由HPV引起的OPSCC血清检测阳性,并且其中1例p16INK4A阳性而HPV DNA阴性。对HR-HPV引起的OPSCC诊断指标的敏感性和特异性分别为:抗E6反应为100%和96%,抗E2反应为 82%和100%,而抗-E7, -E1, -E4和-L1的反应却非常低。3年-整体生存率(OS)和疾病特异性生存率(DSS) 在HR-HPV引发肿瘤的患者(OS 88% vs 64%, p=0.02; DSS 90% vs 80%, p=0.07)和血清阳性患者(OS 88% vs 62%, p=0.01; DSS 92% vs 78%, p=0.05)中较高,明显高于HR-HPV阴性和血清阴性的患者。

结论:HR-HPV亚型特异性抗体与HPV诱发的OPSCC高度相关,并且与良好的存活率有一定的联系。HR-HPV有望成为HR-HPV诱发的OPSCC的诊断和预后指标,并且有成为该病筛选标志物的潜力。

原始出处

Broglie MA, Jochum W, et al. Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer. Oral Oncol. 2017 Jul;70:43-50. doi: 10.1016/j.oraloncology.2017.05.010.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2018-01-07 小几洁
  2. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2018-02-03 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-29 医无止境。

    谢谢分享受益匪浅

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-29 hfuym10906

    学习了。。。。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2020207, encodeId=75ee202020ee4, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Sun Jan 07 08:44:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899137, encodeId=f0f6189913e84, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Aug 09 01:44:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864984, encodeId=4a04186498411, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Feb 03 00:44:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705262, encodeId=195f1e0526248, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Thu Mar 08 00:44:00 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350643, encodeId=e63f13506431c, content=<a href='/topic/show?id=40f2381e4a6' target=_blank style='color:#2F92EE;'>#口咽癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38174, encryptionId=40f2381e4a6, topicName=口咽癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443480, encodeId=dd8314434800e, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526437, encodeId=861e152643e50, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Fri Jun 30 12:44:00 CST 2017, time=2017-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216562, encodeId=4c5b21656221, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Thu Jun 29 07:19:51 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216493, encodeId=e168216493b8, content=学习了。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Thu Jun 29 03:16:21 CST 2017, time=2017-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216471, encodeId=35f92164e1f5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 28 23:55:54 CST 2017, time=2017-06-28, status=1, ipAttribution=)]
    2017-06-28 luominglian113

    学习了,谢谢分享

    0

相关资讯

JAMA Oncol:HPV测试对于非典型鳞状细胞妇女宫颈上皮内瘤样病变干预的影响

研究认为进行人乳头状瘤病毒检测可更快更完整的发现宫颈疾病并及时进行治疗。高度宫颈上皮内瘤样病变患者其HPV阳性率为43.1%,急需相应的临床干预。该研究为宫颈癌筛查指南和公共卫生政策的制定提供了依据

女性健康月㺊种方法帮助女性保持健康

5月是女性健康月,来自康涅狄格大学女性健康中心的专家建议所有女性每天都应该采取行动来维持机体健康并且通过维持以下健康提示来预防乳腺癌及其它癌症。 1、每天锻炼30分钟。研究者Molly Brewer表示,女性维持健康预防疾病首先要做的就是每天进行30分钟的锻炼,其不仅会改善机体的心血管健康,还能够帮助维持健康的体重、体重指数,同

全球领先个指南:接种HPV预防宫颈癌

美国临床肿瘤学会(ASCO)今天发布了人乳头状瘤病毒(HPV)疫苗接种可用于预防宫颈癌的临床实践指南。这是针对世界上具有不同水平的社会经济和结构性资源环境的多个地区定制的子宫颈癌初级预防的第一个指南,为全世界的卫生保健提供者提供循证指导。该指南包括根据资源设置的四个级别的建议:基本,有限,增强和最大。水平涉及一个国家或区域的财政资源以及其卫生系统,包括人员,基础设施和获得服务的机会。该指南补充了A

2017年4月14日Science期刊精华

图片来自Science期刊。2017年4月17日/生物谷BIOON/---本周又有一期新的Science期刊(2017年4月14日)发布,它有哪些精彩研究呢?让小编一一道来。 1.Science:先前的黄病毒感染会增强随后的寨卡病毒感染 doi:10.1126/science.aal4365 一种更加严重的登革热病毒(DENV)感染能够在之前接触过一种不同的DENV血清型的人

JCO:子宫颈上皮内瘤变Ⅲ级者,其它部位的HPV相关肿瘤风险长期持续增加

子宫颈上皮内瘤变(cervical intraepithelial neoplasia CIN):将子宫颈上皮非典型增生至原位癌这一系列癌前病变的连续过程称为子宫颈上皮内瘤变。根据细胞改变程度和异型细胞范围可将CIN分为三级:Ⅰ级为轻度不典型增生,不典型细胞局限于上皮下1/3;Ⅱ级为中度不典型增生,不典型细胞主要位于上皮下1/3~2/3层,细胞极性尚存;Ⅲ级为重度不典型增生和(或)原位癌,病变细胞

Sci Rep:高风险人乳头瘤病毒与乳腺癌

人乳头瘤病毒(HPV)的感染已经牵涉在多种癌症的病因学中。评估乳腺癌(BC)中HPV的存在产生了相当大的争议。到目前为止,大多数研究集中在BC中存在病毒DNA;然而证明HPV在BC侵袭中的作用仍存在巨大的不足。关于此的一些相关研究已经在数个国家中进行,但尚未有关于BC高风险(HR)的HPV的存在和生物活性在英国进行研究。近期,一项发表在杂志Sci Rep上的研究通过使用PCR和Sanger测序方法